Good, better or best - What to choose?

[1]  A. Roguin,et al.  Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. , 2020, JACC. Cardiovascular interventions.

[2]  C. Terkelsen,et al.  Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention , 2020, Circulation.

[3]  M. Stoel,et al.  Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years. , 2020, JACC. Cardiovascular interventions.

[4]  A. Matteau,et al.  Safety and performance of the Orsiro sirolimus eluting stent in the treatment of all-comers patient population in daily clinical practice. , 2020, Cardiovascular revascularization medicine : including molecular interventions.

[5]  S. Pocock,et al.  1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. , 2020, JACC. Cardiovascular interventions.

[6]  M. Stoel,et al.  Thin, Very Thin, or Ultrathin Strut Biodegradable- or Durable-Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. , 2019, JACC. Cardiovascular interventions.

[7]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[8]  M. Stoel,et al.  Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  J. Massaro,et al.  Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients: BIOFLOW V Acute Coronary Syndromes Subgroup , 2018, Circulation. Cardiovascular Interventions.

[10]  A. Roguin,et al.  Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. , 2018, Journal of the American College of Cardiology.

[11]  L. Räber,et al.  Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization , 2018, Circulation. Cardiovascular interventions.

[12]  J. Massaro,et al.  Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial , 2017, The Lancet.

[13]  R. Virmani,et al.  Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. , 2015, European heart journal.

[14]  P. Serruys,et al.  Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents , 2015, Circulation. Cardiovascular interventions.

[15]  K. Stangl,et al.  Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: Results of the Randomized BIOFLOW-II Trial , 2015, Circulation. Cardiovascular interventions.

[16]  J. Brachmann,et al.  Five-year results of the BIOFLOW-III Registry: Real-world experience with a biodegradable polymer sirolimus-eluting stent. , 2019, Cardiovascular revascularization medicine : including molecular interventions.